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Objectives. The intravascular ultrasound (IVUS) substudy of
OARS (Optimal Atherectomy Restenosis Study) was designed to
assess the mechanisms of restenosis after directional coronary
atherectomy (DCA).
Background. Recent serial IVUS studies have indicated that
late lumen loss after interventional procedures was determined
primarily by the direction and magnitude of arterial remodeling,
not by cellular proliferation.
Methods. Complete quantitative coronary angiography (QCA)
and IVUS were obtained in 104 patients before and after inter-
vention and during follow-up. All studies were performed after
administration of 200 mg of intracoronary nitroglycerin. Angio-
graphic measurements included minimum lumen diameter
(MLD), interpolated reference diameter and diameter stenosis
(DS). Intravascular ultrasound measurements included lesion
and reference external elastic membrane (EEM), lumen and
plaque1media cross-sectional area (CSA). The axial location of
the lesion site was at the smallest follow-up lumen CSA; the
reference segment was the most normal-looking cross section
within 10 mm proximal to the lesion but distal to any major side
branch. Results are reported as mean 6 one standard deviation.
Results. The QCA reference decreased from 3.51 6 0.46 mm to
3.22 6 0.44 mm; the MLD decreased from 3.22 6 0.47 mm to
2.03 6 0.72 mm; and the DS increased from 8 6 10% to 38 6 20%.
On IVUS, the decrease in lumen CSA (from 8.8 6 2.5 mm2 to
5.5 6 4.0 mm2) was associated with a significant decrease in EEM
(from 19.7 6 5.6 mm2 to 16.9 6 6.2 mm2); there was no significant
increase in P1M (from 10.9 6 4.2 mm2 to 11.3 6 3.9 mm2). A
change in lumen correlated with a change in EEM (r 5 0.790, p <
0.0001), not with a change in P1M (r 5 0.133, p 5 0.2258). A
decrease in reference EEM (from 19.1 6 7.7 mm2 to 17.6 6
8.0 mm2) also correlated with a decrease in lesion EEM (r 5
0.665, p < 0.0001). Results in restenotic lesions were similar.
Conclusion. Restenosis after optimal DCA is caused primarily
by a decrease in EEM CSA that extends into contiguous reference
segments.
(J Am Coll Cardiol 1998;32:329–37)
©1998 by the American College of Cardiology
The Optimal Atherectomy Restenosis Study (OARS) was a
multicenter study designed to evaluate the mechanisms and
safety of an aggressive directional coronary atherectomy
(DCA) strategy coupled with adjunct percutaneous translumi-
nal coronary angioplasty (PTCA) to enhance the final results.
The protocol included serial intravascular ultrasound (IVUS)
imaging before intervention, after intervention (whether stand-
alone DCA or after adjunct PTCA) and at 6 months to assess
the mechanisms of lumen enlargement and restenosis. Tar-
geted short-term procedural end points were angiographic
residual diameter stenosis (DS) ,10% and IVUS residual
percentage of area occupied by plaque ,50%.
Data from animal models, human autopsy studies, and
analyses of retrieved atherectomy specimens originally sug-
gested that an exaggeration of the normal reparative processes
after angioplasty-induced local vessel trauma leads to uncon-
trolled smooth muscle cell proliferation and restenosis (1–14).
Conversely, recent serial IVUS studies have indicated that late
lumen loss after interventional procedures in nonstented le-
From the Intravascular Ultrasound Imaging and Angiographic Core Labo-
ratories, The Washington Hospital Center, Washington, DC. This study was
supported in part by Devices for Vascular Intervention and by Cardiology
Research Foundation.
Manuscript received December 9, 1996; revised manuscript received Febru-
ary 26, 1998, accepted April 23, 1998.
Address for correspondence: Dr. Martin B. Leon, Director of Research,
Cardiology Research Foundation, 110 Irving Street NW (4B-1), Washington, DC
20010.
JACC Vol. 32, No. 2
August 1998:329–37
329
©1998 by the American College of Cardiology 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(98)00245-9
sions was determined primarily by the direction and magnitude
of arterial remodeling, not by cellular proliferation (15). In
support of this newer hypothesis, endovascular stents, which
scaffold the inner vascular lumen preventing recoil and remod-
eling while exaggerating proliferative responses, have been
shown to reduce restenosis in two randomized clinical trials
(16,17).
We report the serial quantitative coronary angiographic
(QCA) and IVUS analysis of the mechanisms of restenosis
after optimum DCA plus adjunct PTCA from OARS.
Methods
Patient population. Two hundred patients were enrolled in
the OARS study; complete serial IVUS was performed in 104.
Reasons for incomplete serial IVUS study included poor
image quality (in any one study, including difficulty in identi-
fying lumen and media-adventitia borders); failure to cross or
advance the transducer beyond the lesion before intervention,
after intervention or at follow-up; bail-out stenting or emer-
gency coronary artery bypass graft operation; lack of follow-up
angiography; and failure to perform IVUS imaging at angio-
graphic follow-up. Reasons for failure to perform IVUS imag-
ing at follow-up included follow-up angiography performed at
a non-OARS center, clinical instability and reluctance of the
physician to cross a severe lesion or a nonrestenotic “interme-
diate” lesion with the IVUS catheter.
There were 77 men and 27 women, aged 57 6 11 years.
Patient comorbidity rates were unstable angina in 83%, diabe-
tes in 15%, hypertension in 41%, hyperlipidemia in 28% and
cigarette smoking in 33%. Lesion location was left main artery
in 1, left anterior descending artery in 55, left circumflex artery
in 16 and right coronary artery in 32 patients. Lesions in seven
patients were treated previously.
DCA procedure. Atherectomy devices used were 7F in
94% of lesions, with 2.3 6 1.1 catheter passes, 19 6 10 cuts per
lesion and 14 6 8 mg of tissue retrieved. Adjunct PTCA was
performed in 91 patients (87%), with a mean adjunct balloon
size of 3.9 6 0.6 mm.
QCA analysis. All cineangiograms obtained before inter-
vention, after intervention and at follow-up were acquired
after administration of 200 mg of intracoronary nitroglycerin.
Quantitative coronary angiographic analysis was performed by
an independent core laboratory using an automated edge
detection algorithm (CMS, MEDIS) and contrast-filled cathe-
ters as the calibration standard. The minimal lumen diameter
(MLD), interpolated reference diameter and percent DS were
measured before intervention, after intervention and at
follow-up using the two sharpest views showing the stenosis.
Lumen area was then calculated by assuming circular geome-
try. Angiographic restenosis was defined as a follow-up DS $
50% (18).
IVUS imaging systems. All IVUS images were acquired
using one of two commercially available systems. The first
system (InterTherapy/CVIS) used a single-element 25-MHz
transducer coupled with an angled mirror mounted on the tip
of a flexible shaft within a 3.9F short monorail polyethylene
imaging sheath. The second system (Cardiovascular Imaging
Systems) used a 30-MHz beveled transducer within either a
2.9F long monorail imaging sheath (a common distal lumen
alternatively accommodated the imaging core or the guide wire
but not both) or a 3.2F short monorail imaging catheter. With
both systems the transducer was rotated at 1,800 rpm to
produce the tomographic images, and it was withdrawn at
0.5 mm/s within the stationary imaging sheath by using a
motorized transducer pullback device to perform the imaging
sequence. The accuracy of motorized transducer pullback
through a stationary imaging sheath has been validated in vivo
(19). Studies were recorded on 0.5-in. high-resolution super-
VHS videotape for offline analysis.
All IVUS studies obtained before intervention, after inter-
vention and at follow-up were performed after administration
of 200 mg of intracoronary nitroglycerin. The imaging catheter
was advanced approximately 10 mm distal to the lesion, the
motorized transducer pullback device was activated, and com-
plete uninterrupted imaging runs were performed back to the
aorto-ostial junction. This systematic approach facilitated iden-
tification of the target lesion and reference segment image
slices on the serial ultrasound studies for comparative image
analysis.
Quantitative IVUS measurements. Validation of cross-
sectional measurements by IVUS has been reported (20–26).
Using computerized planimetry, we measured the external
elastic membrane (EEM) and lumen cross-sectional areas
(CSA) at the lesion site and at the reference segment. The
plaque1media (P1M) CSA was calculated as EEM minus
lumen CSA. The percentage of area occupied by plaque was
calculated as P1M divided by EEM CSA. The EEM CSA
(representing the area within the border between the hypo-
echoic media and echoreflective adventitia) has been shown to
be a reproducible measure of total arterial area. When the
plaque encompassed the catheter, the lumen was assumed to
be the physical (not acoustic) size of the imaging catheter.
Because media thickness cannot be measured accurately, P1M
CSA was used as a measure of plaque. The percentage of the
total arterial area occupied by plaque has also been termed the
plaque burden or cross-sectional narrowing by other investiga-
tors.
Abbreviations and Acronyms
CSA 5 cross-sectional area
DCA 5 directional coronary atherectomy
DS 5 diameter stenosis
EEM 5 external elastic membrane
IVUS 5 intravascular ultrasound
MLD 5 minimum lumen diameter
OARS 5 Optimal Atherectomy Restenosis Study
P1M 5 plaque 1 media
PTCA 5 percutaneous transluminal coronary angioplasty
QCA 5 quantitative coronary angiography/angiographic
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The same anatomic lesion site and reference segment
image slices were analyzed before intervention, after interven-
tion and at follow-up; differences between time points were
compared. By using one or more reproducible axial landmarks
(eg, the aorto-ostial junction, large proximal or distal side
branches, or uniquely shaped calcium deposits) and a known
pullback speed, identical cross-sectional slices on serial studies
could be identified for comparison. The lesion site image slice
had an axial location within the stenosis at the smallest lumen
CSA at follow-up (rather than at the smallest lumen CSA
before or after intervention). In practice, the follow-up study
was analyzed first to identify the target lesion image slice with
the smallest lumen; then the distance from this anatomic slice
to the closest identifiable axial landmark was measured (using
seconds or frames of videotape); finally, the axial landmark was
noted on the studies obtained before and after intervention,
and the previously measured distance was used to identify the
correct anatomic slice on the studies obtained before and after
intervention. The reference segment image slice was the most
normal-looking cross section (the largest lumen and the small-
est percentage of plaque area) within 10 mm proximal to the
lesion but distal to any major side branch. Once the target
lesion image slice was identified, then the most normal-looking
cross-section within 10 mm proximal to the lesion, but distal to
any major side branch was selected from the study obtained
before intervention. The method of selecting this reference
segment has been reported previously and is designed to select
an ultrasound reference within the arterial segment used to
calculate the angiographic DS (27). The distance between the
target lesion image slice and the reference segment image slice
was measured (using seconds or frames of videotape) and used
to identify the corresponding reference segment image slice on
the IVUS studies obtained after intervention and at follow-up.
Vascular and perivascular markings (often a large side branch
just proximal to the reference segment) confirmed lesion site
and reference segment image slice identification. The serial
studies were analyzed side-by-side and frame-by-frame to
ensure that the same sections were measured. This methodol-
ogy and its reproducibility have been reported previously (15).
Statistics. Statistical analysis was performed using Stat-
View 4.02 (Abacus Concepts). Quantitative data are presented
as mean 6 one standard deviation. Qualitative data are
presented as frequencies. Comparisons of categorical variables
among groups were performed with x2 statistics or Fisher’s
exact test. Comparisons of continuous variables were per-
formed using unpaired Student’s t test, factorial analysis of
variance or analysis of variance for repeated measures. Post-
hoc intergroup comparisons (after analysis of variance for
repeated measures) were performed using paired Student’s t
test with the Bonferroni correction for multiple comparisons
(to maintain an acceptable alpha-type error). A p value , 0.05
was considered significant except for the post-hoc intergroup
comparisons (after analysis of variance for repeated mea-
sures), in which p , 0.017 was considered significant (0.05
divided by 3) (28,29).
Results
Serial QCA results. Before intervention, the mean refer-
ence diameter was 3.39 6 0.47 mm, the MLD 1.21 6 0.39 mm
and the DS 64 6 10%. After intervention, the mean reference
diameter increased to 3.51 6 0.46 mm (p 5 0.0781), the MLD
increased to 3.22 6 0.47 mm (p , 0.0001) and the DS
decreased to 8 6 10% (p , 0.0001). At follow-up, the
reference diameter decreased to 3.22 6 0.44 mm (p 5 0.0154
compared with pre-intervention diameter and p , 0.0001
compared with postintervention diameter), the MLD de-
creased to 2.03 6 0.72 mm (p , 0.0001 compared with both
preintervention and postintervention diameters) and the DS
increased to 38 6 20% (p , 0.0001 compared with both to
preintervention and postintervention diameters (Table 1).
Restenosis was defined as a follow-up DS $50% and was
noted in 28 patients (27%).
Table 1. Quantitative Coronary Angiography and Intravascular Ultrasound Results in 104 Patients
With Complete Studies
Variable
Before
Intervention
After
Intervention Follow-Up p Value
QCA
Reference diameter (mm) 3.39 6 0.47 3.51 6 0.46 3.22 6 0.44*† , 0.0001
MLD (mm) 1.21 6 0.39 3.22 6 0.47 2.03 6 0.72*† , 0.0001
DS (%) 64 6 10 8 6 10 38 6 20*† , 0.0001
IVUS
Reference EEM CSA (mm2) 18.3 6 7.5 19.1 6 7.7 17.6 6 8.0*† , 0.0001
Reference lumen CSA (mm2) 10.2 6 3.9 10.8 6 3.9 9.5 6 4.6*† , 0.0001
Reference P1M CSA (mm2) 8.1 6 4.4 8.4 6 4.6 8.1 6 4.3 0.3973
Lesion EEM CSA (mm2) 17.7 6 5.7 19.7 6 5.6 16.9 6 6.2* , 0.0001
Lesion lumen CSA (mm2) 2.0 6 1.3 8.8 6 2.5 5.5 6 4.0*† , 0.0001
Lesion P1M CSA (mm2) 15.6 6 5.3 10.9 6 4.2 11.3 6 3.9† , 0.0001
*p , 0.017 follow-up versus postintervention. †p , 0.017 follow-up versus preintervention. CSA 5 cross-sectional
area; DS 5 diameter stenosis; EEM 5 external elastic membrane; IVUS 5 intravascular ultrasound; MLD 5 minimum
lumen diameter; P1M 5 plaque1media; QCA 5 quantitative coronary angiography.
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Serial IVUS measurements. Lesion site results. After in-
tervention, 31% of the increase in lumen CSA (from 2.0 6 1.3
mm2 to 8.8 6 2.5 mm2, p , 0.0001) was the result of an
increase in EEM CSA (vessel expansion from 17.7 6 5.7 mm2
to 19.7 6 5.6 mm2, p , 0.0001); and 69% of the increase in
lumen CSA was the result of a decrease in P1M CSA (from
15.6 6 5.3 mm2 to 10.9 6 4.2 mm2, p , 0.0001) (Table 1). The
final percentage of plaque area was 57 6 9%. Nineteen
patients (18%) had a final QCA DS ,10% and a final IVUS
percentage of plaque area ,50%.
At follow-up, the reduction in lumen CSA to 5.5 6 4.0 mm2
(p , 0.0001 compared with both preintervention and post-
intervention lumen CSA) was associated with a decrease in
EEM CSA (to 16.9 6 6.2 mm2, p , 0.0001 compared with
postintervention) and with no increase in P1M CSA to 11.3 6
3.9 mm2 (p 5 0.0656 compared with postintervention). Late
lumen area loss (3.3 6 3.3 mm2) correlated with the decrease
in EEM CSA (2.8 6 3.8 mm2, r 5 0.790, p , 0.0001) but not
with the increase in P1M CSA (0.4 6 2.3 mm2, r 5 0.133, p 5
0.2258) (Fig. 1). The findings in the 97 de novo lesions were
similar.
The serial IVUS changes in the lesions that were restenotic
at follow-up are shown in Table 2. In this subset, the changes
noted in the overall cohort were even more dramatic: a
significant decrease in lumen CSA (p , 0.0001 vs. postinter-
vention), a significant decrease in EEM CSA (p , 0.0001 vs.
postintervention and p 5 0.0023 vs. preintervention) and no
change in P1M CSA (p 5 0.4166 vs. postintervention).
Overall, 22 (20%) of 104 patients had a late increase in
EEM CSA. Lesions with a late increase in EEM CSA were
then compared with lesions with a late decrease in EEM CSA.
This comparison showed (1) similar short-term vessel expan-
sion (2.2 6 3.1 mm2 vs. 2.0 6 1.7 mm2, p 5 0.7454) and
short-term plaque removal (3.7 6 3.2 mm2 vs. 4.8 6 2.6 mm2,
p 5 0.1719); (2) no late lumen loss (0.5 6 3.0 mm2) versus a
4.2 6 2.3 mm2 decrease in lumen CSA (p , 0.0001); (3) similar
postintervention QCA MLD (3.13 6 0.54 mm vs. 3.22 6
0.42 mm, p 5 0.4303) and DS (8 6 13% vs. 7 6 10%, p 5
0.8269); (4) a larger follow-up QCA MLD (2.46 6 0.65 mm vs.
1.88 6 0.68 mm, p 5 0.0014) and a smaller follow-up DS (23 6
17% vs. 41 6 18%, p 5 0.0001); (5) a 5% incidence of
restenosis (compared with a 35% incidence of restenosis in
lesions with a late decrease in EEM CSA, p 5 0.0105); and (6)
a 58% incidence of late lumen gain (compared with a 1%
incidence of late lumen gain in lesions with a late decrease in
EEM CSA, p , 0.0001).
Reference segment results. After intervention, the reference
segment EEM CSA increased slightly from 18.3 6 7.5 mm2 to
19.1 6 7.7 mm2 (p , 0.0001); the reference lumen CSA
increased slightly from 10.2 6 3.9 mm2 to 10.8 6 3.9 mm2 (p 5
Figure 1. Comparison of postintervention to follow-up serial
intravascular ultrasound lesion site results. Change in lumen
CSA (from postintervention to follow-up) correlated with the
change in EEM CSA (r 5 0.790, p , 0.0001) but not with the
change in P1M CSA (r 5 0.133, p 5 0.2258).
Table 2. Results in 28 Lesions That Were Restenotic at Follow-Up
Variable
Before
Intervention
After
Intervention Follow-Up p Value
QCA
Reference diameter (mm) 3.37 6 0.50 3.46 6 0.49 3.16 6 0.43*† , 0.0001
MLD (mm) 1.17 6 0.33 3.16 6 0.50 1.24 6 0.38* , 0.0001
DS (%) 64 6 11 8 6 12 61 6 10* , 0.0001
IVUS
Reference EEM CSA (mm2) 17.3 6 5.3 19.3 6 7.9 17.5 6 8.1*† 0.0005
Reference lumen CSA (mm2) 9.4 6 2.2 10.4 6 3.1 8.8 6 3.0*† 0.0022
Reference P1M CSA (mm2) 8.0 6 4.2 9.0 6 5.6 8.5 6 5.9 0.2361
Lesion EEM CSA (mm2) 16.8 6 5.7 19.2 6 6.0 15.3 6 6.0*† , 0.0001
Lesion lumen CSA (mm2) 1.8 6 1.1 8.3 6 2.4 3.2 6 2.1*† , 0.0001
Lesion P1M CSA (mm2) 15.0 6 5.7 11.0 6 4.5 12.1 6 5.1† , 0.0001
*p , 0.017 follow-up versus postintervention. †p , 0.017 follow-up versus preintervention. Abbreviations as in
Table 1.
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0.0001); and the P1M CSA did not change (8.1 6 4.4 mm2 vs.
8.4 6 4.6 mm2). At follow-up, changes in reference segment
EEM and lumen CSA paralleled the lesion site. There was a
decrease in reference segment EEM CSA (to 17.6 6 8.0 mm2,
p 5 0.0156 compared with preintervention and p , 0.0001
compared with postintervention), a decrease in lumen CSA (to
9.5 6 4.6 mm2, p 5 0.0024 compared with preintervention and
p , 0.0001 compared with postintervention) and no change in
P1M CSA (8.1 6 4.3 mm2). The decrease in reference lumen
CSA (1.3 6 2.0 mm2) correlated with the decrease in EEM
CSA (1.6 6 2.6 mm2, r 5 0.781, p , 0.0001). The decrease in
reference EEM CSA correlated with the decrease in lesion site
EEM CSA (r 5 0.665, p , 0.0001). These results are shown in
Figures 2 and 3.
The changes in reference segments in lesions treated with
stand-alone DCA were similar. At follow-up, there was a
significant decrease in lumen CSA (9.9 6 3.0 mm2 to 7.9 6
2.9 mm2, p 5 0.0109) and a significant decrease in EEM CSA
(17.7 6 5.4 mm2 to 14.8 6 4.0 mm2, p 5 0.0361). The changes
in reference segments in lesions that were restenoic at
follow-up were exaggerated compared with those of the overall
cohort (Table 2), as evidenced by a decrease in EEM CSA
(p 5 0.01 vs. preintervention and p 5 0.0008 vs postinterven-
tion), a decrease in lumen CSA (p 5 0.0143 vs. preintervention
and p 5 0.0003 vs. postintervention) and no change in P1M
CSA. An example of late target lesion and reference segment
changes is shown in Figure 4.
Subset analyses. In lesions restenotic at follow-up com-
pared with lesions not restenotic at follow-up, there was a
greater late decrease in lumen CSA that was associated with a
greater late decrease in EEM CSA but not with a greater
increase in P1M CSA. There were no significant differences in
change in lumen CSA, change in EEM CSA, or change in
Figure 2. Comparison of postintervention to follow-up serial
IVUS reference segment results. Change in lumen CSA (from
postintervention to follow-up) correlated with the change in
EEM CSA (r 5 0.781, p , 0.0001) but not with the change in
P1M CSA (r 5 0.155, p 5 0.1627).
Figure 3. Change in reference segment EEM CSA (from postinter-
vention to follow-up) correlated with the change in lesion site EEM
CSA (r 5 0.665, p , 0.0001).
Table 3. Subset Intravascular Ultrasound Analyses of Changes in
the Cross-sectional Area of Lumen External Elastic Membrane and
Plaque1Media
Comparison N
Change in
Lumen CSA
Change in
EEM CSA
Change in
P1M CSA
Restenotic versus not restenotic
at follow-up
Restenotic 28 5.6 6 2.7 5.2 6 3.6 0.2 6 3.0
Not restenotic 76 2.3 6 3.0 1.9 6 3.1 0.5 6 2.0
p value ,0.0001 ,0.0001 0.5760
De novo versus restenotic
lesions
De novo 97 3.2 6 3.3 2.8 6 3.4 0.5 6 1.9
Restenotic 7 2.6 6 2.1 2.9 6 5.5 0.3 6 5.5
p value 0.6438 0.9608 0.8867
Adjunct PTCA versus stand-
alone DCA
Adjunct PTCA 91 3.3 6 3.3 2.9 6 3.7 0.4 6 2.3
Stand-alone DCA 13 2.5 6 2.6 2.3 6 1.9 1.1 6 2.0
p value 0.4152 0.6519 0.3253
Lesions in diabetics vs
nondiabetics
Lesions is diabetics 16 2.9 6 1.9 1.5 6 1.9 1.8 6 2.0
Lesions in nondiabetics 88 3.2 6 3.4 3.0 6 3.7 0.3 6 2.3
p value 0.7464 0.1879 0.0392
Lesion location
LAD 55 3.2 6 2.4 2.8 6 3.1 0.6 6 1.9
LCx 16 2.7 6 4.2 2.8 6 4.2 0.3 6 2.9
RCA 32 4.3 6 3.2 2.7 6 3.8 0.5 6 2.2
p value (ANOVA) 0.5680 0.9936 0.8546
ANOVA 5 analysis of variance; CSA 5 cross-sectional area; DCA 5
directional coronary atherectomy; EEM 5 external elastic membrane; IVUS 5
intravascular ultrasound; LAD 5 left anterior descending artery; LCX 5 left
circumflex coronary artery; P1M 5 plaque1media; RCA 5 right coronary
artery.
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P1M CSA in (1) patients with new lesions as opposed to
previously treated lesions, (2) in patients treated with stand-
alone DCA compared with patients treated with adjunct
PTCA, and (3) in patients with lesions located in the left
anterior descending artery versus left circumflex coronary
artery versus right coronary artery (there was also no increase
in angiographic restenosis in patients with lesions in the left
anterior descending artery). Similarly, there were no significant
differences between patients with unstable angina and those
with stable angina, between patients with hypercholesterol-
emia and patients without hypercholesterolemia, and between
patients with and without hypertension. There was a greater
increase in P1M CSA in diabetic patients compared with a
tendency for greater decrease in EEM CSA in nondiabetic
patients (although the decrease in lumen CSA was similar in
these two groups, paralleling the similar angiographic resten-
osis rates).
Comparison of minimum lumen area by IVUS compared
with QCA. Before intervention, minimum lumen CSA by
IVUS and QCA correlated moderately well (r 5 0.611, p ,
0.0001), with a mean difference of 0.78 6 1.02 mm2. After
intervention, minimum lumen CSA correlated less strongly
(r 5 0.453, p , 0.0001), with a mean difference of 0.45 6
2.52 mm2. At follow-up, minimum lumen CSA again corre-
Figure 4. Cineangiograms (center)
and IVUS images from a left circum-
flex lesion treated with DCA and ad-
junct PTCA after intervention (A) and
at follow-up (B). Each IVUS image is
accompanied by a duplicate image that
is labeled (bottom images). In each of
the labeled images, the EEM is out-
lined in black, and the lumen is out-
lined in white. A, After intervention,
the proximal reference EEM CSA
measured 11.4 mm2, the lumen CSA
measured 7.4 mm2 and the P1M CSA
measured 4.0 mm2. After intervention,
the lesion site EEM CSA measured
12.9 mm2, the lumen CSA measured
7.1 mm2 and the P1M CSA measured
5.6 mm2. The residual lesion site per-
centage of plaque area was 44%. B, at
follow-up, the reference segment
EEM CSA decreased to 7.0 mm2, the
lumen CSA decreased to 2.5 mm2, and
the P1M CSA increased to 4.5 mm2.
At follow-up, the lesion site EEM CSA
decreased to 6.0 mm2, the lumen CSA
was assumed to be the physical size of
the IVUS imaging catheter (1.0 mm2),
and the P1M CSA increased to
5.0 mm2.
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lated moderately well (r 5 0.623, p , 0.0001), with a mean
difference of 1.91 6 2.67 mm2.
Discussion
Restenosis remains a major limitation to percutaneous
coronary revascularization. The restenotic lesion is thought to
be a proliferative lesion in which an exaggeration of the normal
reparative processes, after angioplasty-induced local vessel
trauma, leads to proliferation of both cellular and matrix
components, causing an increased tissue mass and restenosis
(1,7,10,12–14,30–43). As the understanding of this process has
advanced, attempts have been made to block restenosis by
interfering with this pathologic restenosis cascade (44). Al-
though the results in animal models have been impressive,
pharmacologic trials using antiproliferative agents in humans
have been strikingly ineffective (45–49). In recent animal and
clinical studies, investigators have begun to question the
predominant role of cellular proliferation in restenosis, sug-
gesting that remodeling (the late decrease in arterial CSA)
might result in lumen compromise and might be a major
contributing factor to the development of restenosis (50–60).
Previous serial IVUS restenosis studies. Serial IVUS anal-
ysis has been used to study mechanisms of restenosis (15,61).
In a previous study (15), 73% of the late lumen loss was
accounted for by a decrease in EEM CSA. This decrease in
EEM CSA was termed “remodeling.” Restenotic lesions had a
greater decrease in EEM and lumen CSA, but only a slightly
greater increase in P1M CSA. The change in lumen CSA
correlated more strongly with the change in EEM than with
the change in P1M CSA. The change in EEM CSA was
bidirectional. Despite a greater increase in P1M CSA, lesions
with an increase in EEM CSA had no change in lumen CSA,
increased late lumen gain and decreased restenosis (15). There
were three limitations to that study. First, it was a nonconsec-
utive series of patients; second, it included multiple devices
(balloon angioplasty, DCA, rotational atherectomy and exci-
mer laser angioplasty with and without the use of adjunct
PTCA or DCA); and third, it did not address the time course
of the IVUS events. Kimura et al. (61) reported a consecutive
series of patients treated with PTCA or DCA and studied with
IVUS before intervention and immediately, 24 h, 1 month and
6 months after intervention. That study also showed an in-
crease in EEM CSA (or positive remodeling) between 24 h and
1 month after intervention and a decrease in EEM CSA (or
negative remodeling) between 1 month and 6 months after
intervention. Again, the change in lumen CSA correlated more
strongly with the change in EEM than with the change in P1M
CSA.
Lesion site changes after DCA. The present study is an
analysis of a consecutive series of patients treated with DCA
(with or without adjunct PTCA) in whom IVUS was performed
before intervention, after intervention and at follow-up. Late
lumen loss and restenosis were associated primarily with a
decrease in EEM CSA. Finally, the importance of a late
decrease in EEM CSA was substantiated by the positive impact
of a late increase in EEM CSA (observed in 20% of patients).
Subset analyses substantiated the overall cohort analysis
with one notable exception. In diabetic patients lesions had a
greater increase in P1M CSA than lesions in nondiabetic
patients. This may explain the increased rate of restenosis in
diabetic patients (compared with nondiabetic patients) that
has been noted in previous studies, including one serial IVUS
study (62).
Reference segment changes after DCA (with or without
adjunct PTCA). The QCA and IVUS analyses in the present
series showed that late lumen loss extended into contiguous
reference segments that are typically used to calculate angio-
graphic DS. Two explanations are possible. First, there may be
a diffuse remodeling process after DCA (with or without
adjunct PTCA) that is most severe at the lesion and extends
into the reference segments. Second, because reference seg-
ments were measured within 10 mm of the center of the lesion
and a typical PTCA balloon is 20 mm long, the reference
segments analyzed may have been affected by the interven-
tional procedure.
Dynamic changes in angiographic reference vessel diame-
ters after PTCA have been noted previously (63–65). These
changes have been attributed to technical artifacts (eg, differ-
ences in vasomotor tone or responses to nitroglycerin, inaccu-
rate calibration or different angiographic projections) as well
as to tissue growth within the reference vessel (41). Beatt et al.
(64) showed a late reduction in both the MLD (20.37 mm and
20.42 mm, p , 0.0001) and the reference lumen dimension
(20.17 mm and 20.26 mm, p , 0.0001) at 90 and 120 days,
respectively. Similarly, Nobuyoshi et al. (65) demonstrated a
decrease in both the MLD (20.34 mm, p , 0.001) and
reference lumen (20.17 mm, p , 0.05), which appeared to
stabilize after 6 months. Using the same QCA system as was
used in the current study, Adelman et al. (66) reported a
decrease in reference lumen dimension from 3.15 6 0.46 mm
after intervention (DCA with or without adjunct PTCA) to
3.03 6 0.51 mm at follow-up, less than the 3.51 6 0.46 mm to
3.22 6 0.44 mm decrease in the present study. In Adelman et
al. the final DS was 25.5 6 11.2% (compared with 8 6 10% in
the present study), and adjunct PTCA was used in only 28% of
patients (compared with 87% in the present study). More
aggressive atherectomy, adjunct PTCA, or both in the present
study may account for this difference. With late reductions in
reference dimensions, the percent DS measurement (the con-
ventional index of lesion severity and restenosis) will be
underestimated (64,67–69).
Limitations. The present study represents a subset analysis
from the total cohort of 200 patients in OARS. However, the
demographic data in this subset were not statistically different
from those in the overall OARS cohort for patients (76% men,
78% with unstable angina and 17% with diabetes), lesions
(54% in the left anterior descending artery, 6% restenotic
lesions, QCA reference size of 3.44 mm), procedure (95% 7F
device, 2.3 passes and 19.1 cuts, 15 mg of tissue retrieved and
87% adjunct PTCA with a mean balloon size of 3.9 mm),
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results (QCA final DS, 8%; IVUS percentage of plaque area,
58%) and restenosis rate (29%).
The results of this study were dependent on accurate
identification of the same anatomic cross section on serial
IVUS studies; this requirement precluded blinded analysis.
Identification of the same anatomic cross section on repeated
imaging was ensured by use of a motorized transducer pullback
to a reproducibly recognizable axial landmark at a known
pullback speed coupled with careful attention to lesional and
perilesional markings (and, if necessary, side-by-side and
frame-by-frame comparisons).
Differences in vascular tone could have contributed to
measurement variations of EEM and lumen dimensions. How-
ever, all patients were studied after administration of signifi-
cant doses (200 mg) of intracoronary nitroglycerin; differences
in vascular tone should not have affected measurement of
P1M CSA. In addition, there was little long-term increase in
P1M CSA, even in the restenotic lesions.
In the OARS study, time course of the changes in EEM
CSA were not obtained; therefore, remodeling could not be
separated from passive elastic recoil. In the present study,
lesion site EEM CSA at follow-up was not statistically com-
pared with preintervention. However, the SURE (serial ultra-
sound restenosis) Trial studied patients treated with PTCA
and DCA before and immediately after intervention, 24 h after
intervention, and after 1 and 6 months of follow-up. There was
little change in EEM CSA within the first 24 h after interven-
tion, an increase in EEM CSA between 24 h and 1 month and
a decrease in EEM CSA between 1 and 6 months (63). As in
the present study, the changes in follow-up lumen CSA paral-
leled the changes in EEM CSA, but not the changes in P1M
CSA. Lastly, in the SURE Trial serial measurements of the
reference segment EEM CSA paralleled measurements of the
lesion site EEM CSA, supporting a similar finding in OARS.
The ABACAS (Adjunct Balloon Angioplasty Coronary
Atherectomy Study, Fitzgerald, personal communication) in-
cluded postintervention, 3-month and 6-month IVUS analysis.
Preliminary results show that EEM CSA increased between
postintervention and 3 months and decreased between 3
months and 6 months. Thus, in both SURE and ABACAS
there is first an increase in the EEM CSA early in the follow-up
period followed by a decrease in the EEM CSA late in the
follow-up period. Therefore, the late decrease in EEM CSA is
distinct from passive elastic recoil.
Intravascular ultrasound can only measure net changes in
the P1M CSA; therefore, cellular proliferation and apoptosis
(or lesion contraction) could coexist, and cellular proliferation
could go unrecognized. Similarly, IVUS can measure only the
changes in EEM CSA; therefore, it cannot separate the effect
of active adventitial constriction from a passive response to a
decrease in P1M CSA.
In the present study we could not definitively separate the
long-term effects of DCA from those of adjunct PTCA. There
were few lesions treated with DCA alone. However, prelimi-
nary results of ABACAS also showed no difference (in serial
IVUS results) between lesions randomly assigned to receive
adjunct PTCA and lesions randomly assigned to stand-alone
DCA.
Some of the changes in IVUS cross-sectional measurements
were small.
Conclusions. Late lumen loss after DCA (with or without
adjunct PTCA) appeared to be associated mainly with a
decrease in EEM CSA rather than with plaque regrowth. The
changes in EEM CSA were paralleled by similar but smaller
changes in contiguous reference segments.
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